iRhythm (IRTC) Q2 2026 Earnings Call Transcript
iRhythm (IRTC) reported Q2 2026 revenue of $224.2M, up 20.1% YoY, with gross margin at 72.8%. GAAP net loss was $0.4M, and adjusted EBITDA was $43.3M. Full-year revenue guidance is $880M to $890M and adjusted EBITDA margin 13% to 14%. The company agreed to acquire VitalConnect for about $287.5M and received a $50M Baxter settlement.
How this was made
The 30-second read
Why it matters
Traders can reprice the stock based on the combination of (1) updated revenue and EBITDA margin guidance, (2) a defined acquisition consideration and expected revenue run-rate timing, and (3) risk factors including FDA warning letter oversight and cybersecurity incident containment.
Market read
The call is a multi-catalyst update: guidance plus a material acquisition and settlement, with explicit margin and productivity drivers tied to a newly cleared third-generation algorithm.
What to watch
Deal execution risk (integration, customer adoption, and timing of VitalConnect revenue ramp in 2027) and potential ongoing remediation costs could pressure margins despite the stated EBITDA leverage.
Background
iRhythm reported Q2 2026 results and used the call to update full-year and third-quarter guidance while announcing a VitalConnect acquisition and addressing regulatory, litigation, and cybersecurity items.
Ticker impact
iRhythm guided FY revenue to $880M-$890M and disclosed a definitive VitalConnect acquisition plus a $50M Baxter settlement.
Likely positive bias on valuation from growth guidance and deal expansion, offset by regulatory and integration risk.
Fresh, decision-relevant disclosures include FY and Q3 guidance, VitalConnect consideration and expected 2027 revenue contribution, and a Baxter settlement. However, the transcript also flags ongoing FDA warning letter oversight, which can cap upside until remediation progress is clearer.
Market effects
Supports the mobile cardiac telemetry and remote monitoring theme via expansion into inpatient monitoring and hospital-to-home programs.
Primarily US healthcare delivery and reimbursement dynamics, given the arrhythmia risk population and EHR integration focus.
Limited direct global impact, but reinforces US medtech/healthcare IT adoption trends.
Counterpoint
The acquisition and algorithm clearance claims may not fully offset regulatory overhang from the FDA warning letter, making the guidance path contingent on remediation progress.
Key entities
- companyiRhythm Technologies, Inc.
Subject of the earnings call, providing Q2 results, FY/Q3 guidance, and deal/regulatory updates.
- acquired_companyVitalConnect
Mobile cardiac telemetry/wearable capability target; acquisition consideration and expected 2027 revenue contribution were disclosed.
- counterpartyBaxter
Litigation counterparty; settlement payment of $50M was disclosed.
- regulatorFDA
Regulatory body referenced via an ongoing warning letter and review process.
